Therapy of Acute Lymphoid Leukemia (ALL) of the young adult: treatment intensification According to the AIEOP LAL 2000 Pediatric Protocol: LAL 1308 Protocol

Project objectives

Primary objective: Evaluation of the feasibility of the protocol - inspired by the AIEOP LLA-2000 pediatric protocol - in young adults (age _18 and <35 years) with ALL, mature non-B, non-Ph+ in terms of proportion of patients in the protocol, alive and in complete remission, eligible to continue it 8 months after diagnosis. Secondary objectives:

  • Evaluate the CR rate at the end of induction therapy

  • Estimate Overall Survival (OS), Disease-Free Survival (DFS), and Event-Free Survival (EFS)

  • Retrospective comparison of the results with those obtained in patients with the same clinical characteristics included in the GIMEMA protocols

  • Evaluate the toxicity (grade III-IV) of the re-induction phase including Adriblastine and Dexamethasone

  • Evaluate treatment compliance in terms of dose intensity (cumulative drug doses; therapy intervals).

Start and end date

26/01/2011 - 02/05/2016

Project Manager

Prof. Giuseppe Avvisati

Coordinating institution of the project

Policlinico Umberto I, Rome - Hematology

Other Institutions involved

Institutions belonging to the Italian Group of Adult Hematological Diseases (GIMEMA)

Funding source(s).

GIMEMA Foundation